Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.71 |
| ▸ | CES1 | P23141 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | FYN | P06241 | 1/20 | 0.68 |
| ▸ | DAO | P14920 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL6968596 | 0.93 | LCK (0.67) | CES2CES1LCKFYNDAO | |
| Oxalic Acid SCHEMBL6968894 | 0.91 | LCK (0.64) | CES2CES1LCKFYNDAO | |
| Oxalic Acid SCHEMBL7445055 | 0.91 | LCK (0.64) | CES2CES1LCKFYNDAO | |
| SCHEMBL838599 | 0.89 | LCK (0.61) | CES2CES1LCKFYNDAO | |
| SCHEMBL6966883 | 0.87 | LMNA (0.62) | CES2CES1LCKFYNDAO | |
| SCHEMBL20448559 | 0.85 | SRD5A2 (0.55) | CES2CES1LCKFYNDAO | |
| SCHEMBL31612030 | 0.85 | CES2 (0.54) | CES2CES1LCKFYNDAO | |
| SCHEMBL6956689 | 0.85 | CES2 (0.54) | CES2CES1LCKFYNDAO | |
| SCHEMBL17100305 | 0.85 | CES2 (0.54) | CES2CES1LCKFYNDAO | |
| SCHEMBL10369523 | 0.85 | ALDH1A1 (0.64) | CES2CES1LCKFYNDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105143227-A | Substituted imidazo [1,2-B ] pyridazines as MKNK1 inhibitors | Bayer Pharma AG | 2015-12-09 | — | — | CN | claimed |
| CN-104016898-A | 3,4-disubstituted pyrrole compound as well as preparation method and application thereof | UNIV SHANGHAI JIAOTONG | 2014-09-03 | — | — | CN | claimed |
| CN-101910173-A | 2-heteroaroyl imidazo [1,2-a ] pyridine derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS | 2010-12-08 | — | — | CN | claimed |
| CN-1914173-A | Quinolines useful in treating cardiovascular disease | WYETH CORP (US) | 2007-02-14 | — | — | CN | claimed |
| CN-119630673-A | PDE4B inhibitors and uses thereof | 西藏海思科制药有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240368001-A1 | SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2024-11-07 | — | — | US | disclosed |
| US-11987506-B2 | Salt recovery solution and processes of use thereof | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2024-05-21 | — | — | US | disclosed |
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230257284-A1 | SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2023-08-17 | — | — | US | disclosed |
| CN-116282078-A | Salt recovery solution and method of using the same | 阿克福特斯技术有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-111225875-B | Salt recovery solution and method of using salt recovery solution | 阿克福特斯技术有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20230043356-A1 | A SOLVENT DRYING COMPOSITION AND PROCESSES THEREFOR | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2023-02-09 | — | — | US | disclosed |
| EP-0842923-A1 | PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997025033-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5631264-A | NEUROLOGICAL DISORDERS | SANOFI WINTHROP, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5604224-A | NEURODEGENERATIVE DISORDERS | STERLING WINTHROP INC. (US) | 1997-02-18 | — | — | US | disclosed |
| US-5569655-A | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1996-10-29 | — | — | US | disclosed |
| US-5554620-A | Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof | STERLING WINTHROP INC. (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0656359-A1 | Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof | STERLING WINTHROP INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0647641-A1 | Substituted heterocyclylisoquinolinium salts and compositions and methods of usethereof | STERLING WINTHROP INC. (US) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043356-A1 | A SOLVENT DRYING COMPOSITION AND PROCESSES THEREFOR | AQP1, AQP4, NOTUM | CES2 3096/4885CES1 2468/4885LCK 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.